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Relapsing-remitting multiple 
sclerosis patients display an 
altered lipoprotein profile with 
dysfunctional HDL
Winde Jorissen1, Elien Wouters1, Jeroen F. Bogie1, Tim Vanmierlo1, Jean-Paul Noben1, 
Denis Sviridov2, Niels Hellings1, Veerle Somers1, Roland Valcke3, Bart Vanwijmeersch4, 
Piet Stinissen1, Monique T. Mulder5, Alan T. Remaley2 & Jerome J. A. Hendriks1
Lipoproteins modulate innate and adaptive immune responses. In the chronic inflammatory disease 
multiple sclerosis (MS), reports on lipoprotein level alterations are inconsistent and it is unclear 
whether lipoprotein function is affected. Using nuclear magnetic resonance (NMR) spectroscopy, we 
analysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS patients and 
healthy controls (HC). We observed smaller LDL in RRMS patients compared to healthy controls and 
to progressive MS patients. Furthermore, low-BMI (BMI ≤ 23 kg/m2) RRMS patients show increased 
levels of small HDL (sHDL), accompanied by larger, triglyceride (TG)-rich VLDL, and a higher lipoprotein 
insulin resistance (LP-IR) index. These alterations coincide with a reduced serum capacity to accept 
cholesterol via ATP-binding cassette (ABC) transporter G1, an impaired ability of HDL3 to suppress 
inflammatory activity of human monocytes, and modifications of HDL3’s main protein component 
ApoA-I. In summary, lipoprotein levels and function are altered in RRMS patients, especially in low-BMI 
patients, which may contribute to disease progression in these patients.
Lipoproteins are crucial mediators of cholesterol transport and play an important role in the regulation of inflam-
matory responses. High density lipoprotein (HDL) has anti-atherogenic properties that are primarily attributed to 
its key role in reverse cholesterol transport. Furthermore, HDL has anti-inflammatory effects on monocytes and 
endothelial cells, has anti-oxidant properties, and HDL’s main associated protein, ApoA-I, reduces inflammation 
in the central nervous system (CNS) by preventing contact between T cells and macrophages1–4. HDL consists of 
heterogeneous subclasses which can be identified based on their density, charge, size, and protein composition5. 
Importantly, changes in HDL subclass distribution go together with alterations in the levels of other plasma lipo-
proteins6–9, and are often associated with HDL dysfunction as is observed in chronic inflammatory diseases like 
type 2 diabetes (T2D) and atherosclerosis10–25.
Multiple sclerosis (MS) is an autoimmune disease, characterized by chronic inflammation and demyelination 
in the central nervous system (CNS). Relapsing-remitting MS (RRMS) is the most frequent (80–90%) occurring 
type of MS, and is characterized by unpredictable periods of inflammatory relapse and remission phases. In most 
RRMS patients, the disease gradually progresses with an increased number of relapses (i.e. Progressive Relapsing 
MS (PRMS)), towards a progressive disease course characterized by more prominent role for neurodegeneration 
compared to inflammation (i.e. secondary progressive MS (SPMS))26. The onset and progression of multiple scle-
rosis (MS) is presumed to be driven by an autoreactive immune response. HDL may interfere with these processes 
by multiple mechanisms such as its ability to modulate monocyte and T cell responses3,27–30.
Despite the chronic inflammatory character of MS, it is poorly understood if and how lipoprotein levels, 
subclasses, and function are altered in MS patients, and whether such changes influence disease progression. 
Notably, Penesova and colleagues recently described decreased insulin sensitivity and postprandial hyperin-
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sulinemia in MS patients31. Reduced insulin sensitivity is typically associated with lipoprotein abnormalities32. 
Interestingly, a positive association between patient disability and plasma LDL, ApoB, and total cholesterol lev-
els is observed in MS patients33–35. In addition, higher serum HDL was found to be associated with lower lev-
els of blood-brain-barrier injury and decreased cell extravasation into the CSF30. Reports on HDL levels in MS 
patients are however inconsistent. Whereas some studies report an increase36,37, others suggest a decrease38, or 
show no change in HDL levels39. These contradictory findings may be partially explained by the lack of distinction 
between different HDL subclasses. Importantly, increased levels of oxidized LDL in the plasma and CNS40,41 and 
higher serum levels of auto-antibodies against oxidized LDL39 are observed in MS patients. In line with this, the 
loss of HDL anti-oxidant function in MS patients is suggested41,42, indicating that lipoprotein function may also 
be affected.
In this study, nuclear magnetic resonance (NMR) spectroscopy was used to determine the lipoprotein profile 
of relapsing-remitting MS (RRMS) patients, progressive MS patients and healthy controls (HC). Furthermore, 
HDL function was assessed and HDL’s main protein component, ApoA-I, was analyzed using liquid chroma-
tography–mass spectrometry (LC-MS/MS). We show an altered lipoprotein profile in RRMS patients, especially 
pronounced in low-BMI RRMS patients, with dysfunctional HDL that is modified at its ApoA-I tyrosine and 
tryptophan residues.
Results
RRMS patients have smaller LDL particles. The different lipoproteins and their subclasses, as well as a 
lipoprotein-based insulin resistance index (LP-IR) were determined in RRMS patients, progressive MS patients, 
and healthy controls by NMR. Table 1 provides an overview of characteristics of the study population and of their 
lipid and lipoprotein profile. RRMS patients show smaller LDL and in line with this a lower level of large LDL 
particles compared to controls and progressive MS patients. No other significant differences between the groups 
were found for the measured lipoprotein subclasses, LP-IR index, BMI, or male-to-female ratios. Progressive MS 
patients were significantly older (P < 0.01) than HC and RRMS patients. Therefore, age was added as a possible 
covariate to the regression models in further analyses.
HC RRMS Prog MS
N 89 36 25
Age 42.0 ± 1.5 42.0 ± 1.7 51.7 ± 1.7**, ††
Male gender, % 38 (43%) 10 (28%) 11 (44%)
BMI 24.9 ± 0.4 25.9 ± 0.7 24.5 ± 0.9
Conventional lipid panel
 Total cholesterol, mg/dl 182.7 ± 3.8 169.6 ± 5.3 187.4 ± 7.9
 Triglycerides, mg/dl 113.6 ± 6.1 136.6 ± 17.8 106.2 ± 5.6
 HDL-c, mg/dl 61.0 ± 1.7 59.3 ± 2.3 60.8 ± 3.5
 LDL-c, mg/dl 109.8 ± 3.8 96.6 ± 4.8 115.6 ± 6.3
Lipoprotein subclasses
HDL
 Size nm 9.5 ± 0.1 9.4 ± 0.1 9.5 ± 0.1
 Total particle count, μ mol/L 35.8 ± 0.6 36.3 ± 0.9 34.2 ± 1.1
 Small particle count, μ mol/L 14.9 ± 0.9 15.2 ± 1.4 15.7 ± 1.2
 Medium particle count, μ mol/L 12.1 ± 0.8 12.8 ± 1.3 9.0 ± 1.3
 Large particle count, μ mol/L 7.5 ± 0.4 7.1 ± 0.5 8.1 ± 0.7
LDL
 Size, nm 21.0 ± 0.1 20.6 ± 0.1*, ‡ 21.0 ± 0.1
 Total particle count, nmol/L 1, 182 ± 44.9 1, 099 ± 60.4 1, 217 ± 67.2
 Small particle count, nmol/L 463.9 ± 34.8 517.0 ± 62.7 418.2 ± 69.5
 Large particle count, nmol/L 432.9 ± 24.3 312.1 ± 39.8*, ‡‡ 503.7 ± 51.4
IDL
 Particle count, nmol/L 166.7 ± 11.9 157.1 ± 18.1 170.6 ± 24.8
VLDL
 Size, nm 51.5 ± 0.8 53.6 ± 1.6 50.78 ± 1.2
 Total particle count, nmol/L 43.9 ± 2.8 48.9 ± 4.4 41.2 ± 3.5
 Small particle count, nmol/L 22.3 ± 1.5 24.9 ± 2.4 22.9 ± 2.5
 Medium particle count, nmol/L 17.6 ± 1.8 17.6 ± 2.2 15.3 ± 1.7
 Large particle count, nmol/L 5.0 ± 0.5 7.3 ± 1.7 4.2 ± 0.7
 VLDL-Triglycerides, mg/dl 78.7 ± 5.2 100.6 ± 15.3 70.8 ± 5.2
LP-IR index (0–100) 45.9 ± 2.5 50.9 ± 3.5 41.2 ± 3.8
Table 1.  Descriptive statistics for the study population. Values are means ± SEM. HC = healthy controls; 
RRMS = relapsing-remitting MS; Prog MS = progressive MS. * versus controls (*P < 0.05, **P < 0.01); †† versus 
RRMS (††P < 0.01), ‡‡versus progressive MS (‡‡P < 0.01).
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RRMS patients with a low BMI have smaller HDL particles. To correct the measured lipoprotein 
parameters for the difference in age and to determine possible other confounding effects of the independent 
covariates “gender”, “BMI”, and “group”, and possible interactions between these covariates, we performed uni-
variate multiple linear regression analyses for each measured lipoprotein subclass. The lipoprotein parameters 
for which a significant contribution of covariates was found, are shown in Table 2. Based on the fitted models, 
the mean size of LDL (LDL-z, nm) is smaller in RRMS patients compared to healthy controls and progressive 
MS patients of the same gender. Furthermore, RRMS patients have a lower amount of large LDL particles (Large 
LDL-p, nmol/l) compared to controls and progressive MS patients of the same age and gender. In addition, sHDL 
particle count (sHDL-p, μ mol/L) is increased in the plasma of RRMS patients within a distinct BMI range com-
pared to controls with the same BMI. More specific, RRMS patients with a low BMI ( ≤ 23 kg/m2) displayed an 
increase in sHDL compared to low-BMI controls of the same gender. The BMI threshold for differences in sHDL 
was determined based on the confidence bands of the regression lines describing the relationship between sHDL 
and BMI, distinguishing between groups (Fig. 1), and was similar for male and female subjects. Interestingly, 
these regression lines show a negative relation between sHDL-p and BMI for RRMS patients, whereas this relation 
is positive for HC, and neutral for progressive MS patients. Within each group (e.g. RRMS, progressive MS and 
controls), lipoprotein alterations were more pronounced in male than in female subjects. Altogether, our data 
show that LDL particle distribution of RRMS patients is shifted towards smaller LDL particles as they show a 
decrease in large LDL, together with a decrease in LDL size. In addition, low-BMI RRMS patients display a shift 
towards increased levels of sHDL.
RRMS patients with a low BMI display an insulin resistant-like lipoprotein profile. An increase in 
the amount of sHDL is often accompanied by other changes in the lipoprotein profile, such as observed in patients 
with T2D43,44. For this reason, we performed univariate multiple linear regression analyses for all of the lipoprotein 
Response Cholesterol 
Parameter
CONFOUNDING PARAMETERS for the Study Population
Age Gender Group Group*BMI
LDL-z (nm) F > M† *** RRMS < HC
‡ * and 
RRMS < Prog MS‡ *
Large LDL-p (nmol/L) ↑ with age 
§ 
y = 167.3 + 4.5x F > M
|| ** RRMS < HC 
# ** and 
RRMS < Prog MS‡ *
Small HDL-p (μmol/L) M > F& **** RRMS > HC
‡ with a 
BMI ≤ 23*
Table 2.  Fitted univariate multiple regression models for the study population. †for individuals of the same 
group; ‡ of the same gender; § of the same group and gender, || of the same group and age; # of the same age and 
gender; &of the same group and BMI. - z = particle size; - p = particle count; M = male; F = female. Responses 
are shown only when the covariate “Group” was among the confounders. The interactions Age*Gender, 
Age*BMI, Age*Group and BMI*Gender were not confounding for any of the shown responses. *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001.
Figure 1. RRMS patients display an inverse relationship between BMI and sHDL-p. The regression line 
describing the relationship between sHDL and BMI, distinguishing between groups (i.e. HC (n = 89, black), 
RRMS (n = 35, red), and Prog MS (n = 25, green)), for females (a) and males (b) is shown. The dotted vertical 
line shows the threshold for BMI for which RRMS patients and HC differ significantly in their amount of 
sHDL-p. - p = particle count.
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parameters measured with NMR for low-BMI controls (n = 29), RRMS patients (n = 10) and progressive MS 
(n = 11) patients. In addition to the above mentioned increase in sHDL, RRMS patients with a low BMI showed 
a higher LP-IR, larger VLDL particles (nm), and an increased amount of TG (mg/dl) and VLDL-TG (mg/dl) 
compared to controls and to progressive MS patients (Table 3). No differences were found in HDL cholesterol 
(HDL-c) or LDL-c levels. Interestingly, a positive correlation between the amount of sHDL-p and sLDL-p levels in 
RRMS patients with a low BMI (r = 0.5, P = 0.05) was observed, and the LP-IR of these patients correlated nega-
tively with HDL-c (r = − 0.6, P = 0.05), and positively with concentrations of TG (r = 0.7, P = 0.01) and VLDL-TG 
(r = 0.7, P = 0.01) (data not shown), hereby highlighting the interdependency of these lipoprotein parameters. 
Altogether, these data show that lipoprotein levels are especially altered in RRMS patients with a low BMI.
RRMS patients show normal LCAT mass. Lecithin - cholesterol acyltransferase (LCAT) mediates the 
esterification rate of free cholesterol onto lipid poor HDL particles, hereby increasing the size of HDL parti-
cles. LCAT mass is highly correlated with its enzyme activity and with its molar cholesterol esterification rate45. 
RRMS patients did not show alterations in LCAT mass compared to healthy controls (Fig. 2a), indicating that the 
observed increase in sHDL in RRMS patients cannot be explained by alterations in LCAT mass. Furthermore, age, 
gender, and BMI had no confounding effect on LCAT mass.
Serum of RRMS patients has a reduced capacity to accept cholesterol via the ABCG1 trans-
porter. Cellular reverse cholesterol transport determines the inflammatory phenotype of monocytes. sHDL 
measured by NMR in our study are predominantly alpha 3 (α − 3) and alpha 4 (α − 4) HDL particles that efflux 
cholesterol via the ATP-binding cassette G1 (ABCG1) transporter (Fig. 2b). To determine whether changes in the 
quantity of sHDL in RRMS patients with a low BMI are associated with changes in HDL function, we made use of 
a physiologically relevant assay to analyze the capacity of serum from RRMS patients to accept cholesterol from 
3H-cholesterol labeled BHK cells transfected with human ABCA1 or ABCG1. Our data show that the capacity of 
serum lipoproteins to accept cholesterol via the ABCA1 transporter is similar between healthy controls, RRMS, 
and progressive MS patients (Fig. 2c). However, serum cholesterol efflux capacity via the ABCG1 transporter was 
reduced in RRMS patients compared to controls and progressive MS patients (Fig. 2c).
In addition to the serum cholesterol acceptance capacity, cellular ABC transporter expression contributes to 
the efflux capacity of monocytes. Therefore, we analyzed mRNA expression levels of the ABC transporters on 
monocytes of MS patients and controls. Whereas no changes in the expression of ABCA1 mRNA were observed 
between groups, the expression of ABCG1 was significantly (P < 0.05) lower on monocytes of RRMS patients 
compared to monocytes of healthy controls (Fig. 2d). Furthermore, in line with the increase in sHDL in low-BMI 
RRMS patients, we found a strong negative correlation between the amount of sHDL in the plasma and the 
capacity of serum to accept cholesterol via the ABCG1 transporter in RRMS patients with a low BMI (r = − 0.94, 
P < 0.0001) (Fig. 2e). This correlation was not significant for control (r = − 0.07, P = 0.67) or RRMS subjects 
(r = 0.04, P = 0.84) with a BMI higher than 23, nor for controls with a low BMI (r = − 0.39, P = 0.09) (data not 
shown). These findings indicate that ABCG1-mediated cholesterol efflux capacity is reduced in RRMS patients, 
both at serum and at cellular level.
HDL3 of low-BMI RRMS patients has a reduced capacity to suppress pro-inflammatory gene 
expression of human monocytes. Subsequently, we determined whether HDL3 from low-BMI RRMS 
patients retained its anti-inflammatory effects on human monocytes. To this end, we assessed the capacity 
of HDL3 to suppress the expression of pro-inflammatory genes that are involved in MS pathology by mono-
cytes46,47. Our data show that, in contrast to sHDL from HC, sHDL from RRMS patients was not capable to 
suppress inflammation-induced pro-inflammatory gene expression of tumor necrosis factor alpha (TNFα ), 
CD40, IL1β , and IFNγ in monocytes obtained from healthy controls (Fig. 3). These results demonstrate that 
the anti-inflammatory capacity of HDL3 is reduced in RRMS patients with a low BMI. Additionally, the reduced 
anti-inflammatory capacity of HDL3 of low-BMI RRMS patients was validated for TNFα protein levels (see: 
Supplemental Data Fig. 1). No effects of HDL3 of low-BMI HC or RRRMS patients were observed on monocyte 
expression levels of the anti-inflammatory genes CD163, CD206, and TGFβ (see: Supplemental Data Fig. 2).
Tyrosine and tryptophan residues of ApoA-I in HDL3 of RRMS patients are modified. 
Inflammation-induced modifications of HDL proteins are shown to affect its function12,22,48,49. To identify possible 
Response Cholesterol 
Parameter Controls (n = 29) RRMS (n = 10) Prog MS (n = 11)
LP-IR (0–100) 40.98 ± 3.47 67.50 ± 9.10*, †† 31.47 ± 6.75
TG (mg/dl) 100.86 ± 7.98 264.44 ± 20.73 ****, †††† 99.22 ± 15.37
VLDL-TG (mg/dl) 71.30 ± 6.47 197.98 ± 17.00****, †††† 58.88 ± 12.60
VLDL-z (nm) 51.09 ± 1.52 63.49 ± 3.99*, † 49.05 ± 2.96
HDL-c (mg/dl) 63.59 ± 3.02 59.09 ± 5.28 67.88 ± 4.9
LDL-c (mg/dl) 99.68 ± 6.32 104.2 ± 10.76 126.73 ± 10.26
Table 3.  Insulin resistant-like risk factors in low-BMI RRMS patients. Values are means ± SEM. -z = particle 
size; -c = cholesterol; *versus controls (*P < 0.05, ****P < 0.0001); †versus Prog MS (†P < 0.05, ††P < 0.01, 
††††P < 0.0001).
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protein changes on HDL of RRMS patients, ApoA-I tryptic peptides were analyzed for possible modifications 
with LC-MS/MS. ApoA-I of RRMS patients showed nitration on its Trp-50 residue (Fig. 4a). Furthermore, 
mono-, di-, and tri-oxidated peptides were detected on both Trp-50 (Fig. 4b,c and d respectively) and 
Figure 2. RRMS patients have reduced serum cholesterol efflux capacity via ABCG1 and reduced monocyte 
ABCG1 mRNA expression compared to healthy controls. (a) LCAT mass (μ g/ml) was measured in freshly 
thawed plasma samples of HC (n = 21) and RRMS (n = 22) patients using ELISA. (b) Schematic representation 
of sHDL measured by NMR, based on 2D gelelectrophoresis, and ultracentrifugal separation. (c) Capacity of 
serum from controls (n = 50), RRMS (n = 26), and progressive MS (n = 17) patients to accept cholesterol via 
the ABCA1 (left) or ABCG1 (right) transporters from 3H-cholesterol loaded BHK cells transfected with human 
ABCA1 or ABCG1 respectively. (d) Basal ABCA1 (left) and ABCG1 (right) mRNA expression in monocytes 
of HC (n = 43), RRMS (n = 33), and progressive MS (n = 7) patients measured using quantitative PCR (qPCR). 
Results are expressed as fold change of healthy controls. (e), Pearson correlation coefficient for percentage 
serum cholesterol efflux capacity via the ABCG1 transporter versus sHDL (μ mol/L) for RRMS patients with a 
low BMI (n = 10). *P < 0.05, ****P < 0.0001.
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Trp-72 (see: Supplemental Data Fig. 3). In addition, we identified nitrations on Tyr-18, 29, 166, and 236 (see: 
Supplemental Data Fig. 4), and a modification on Tyr-18, 29, 100, 115, 166, and 236, corresponding to a mass 
increase of 126 atomic mass units (amu) (see: Supplemental Data Figure 5). An overview of the mentioned mod-
ification sites along the protein sequence of mature ApoA-I is shown in Fig. 4e. Altogether, our results show 
that HDL of RRMS patients is modified on its ApoA-I tyrosine and tryptophan residues, which may affect HDL 
function.
Discussion
In this study, we determined whether lipoprotein levels and HDL function are altered in MS patients. Our data 
show that RRMS patients have smaller total LDL compared to healthy controls and to progressive MS patients, as 
a result of the reduced number of large LDL particles. The progressive MS patients are significantly older than the 
HC and RRMS patients. As we found that large LDL particle count increases with age, the difference in large LDL 
particle count between progressive and relapsing-remitting MS patients, but not between HC and RRMS patients, 
can be due to age. Smaller LDL particles are described to have an increased susceptibility to oxidation50,51 and a 
decreased LDL receptor affinity52 which can promote pro-inflammatory properties of LDL in RRMS patients. In a 
subgroup of RRMS patients with a low BMI (BMI ≤ 23 kg/m2), a higher level of sHDL, accompanied by increased 
levels of TG, large VLDL, and VLDL-TG, and a higher LP-IR was observed. This corresponds to the findings 
of Palavra and colleagues who observed an increase in sHDL and TG in the total RRMS patient population41. 
Interestingly, in their study population the average BMI of RRMS patients was lower (e.g. 23.75 kg/m2) compared 
to our study population (e.g. 25.9 kg/m2), which may explain why they observed an increase of sHDL in the total 
RRMS group and we only found this increase in the low-BMI group. Although the number of low BMI patients in 
the RRMS group was relatively low (n = 10), the finding that low BMI patients differ significantly from the other 
subjects was calculated based on the entire group of controls (n = 89) and patients (n = 36 RRMS, n = 25 pro-
gressive MS), and the statistical model predicting the effect observed in the group of RRMS patients was highly 
Figure 3. HDL3 of low-BMI RRMS patients does not suppress inflammation-induced gene expression 
of TNFα, CD40, IL1β, and IFNγ. Human monocytes from healthy donors were isolated from fresh blood 
samples. Monocytes of HC were pre-incubated with pooled HDL3 (60 mg/dl) isolated from low-BMI control 
subjects (n = 8) or low-BMI RRMS patients (n = 9) in low serum culture medium for four days followed by 
an overnight LPS (100 ng/ml) stimulus. Monocyte gene expression was measured using qPCR. Results are 
expressed as fold change of control LPS conditions without HDL3. HC = healthy controls; RRMS = relapsing-
remitting multiple sclerosis; LPS = lipopolysaccharide. *P < 0.05, †versus control LPS ( = 1) (†P < 0.05, 
††P < 0.01).
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significant. It would be interesting to perform a larger study in which the focus lies on low-BMI RRMS patients 
in order to gain more insight into potential variables contributing to the altered lipoprotein profile observed in 
this specific subgroup of MS patients. LCAT mass, being highly correlated with its enzyme activity and its molar 
cholesterol esterification rate45, could not explain the observed increase in sHDL in low-BMI RRMS patients. 
Of note, cholesteryl ester transfer protein (CETP) activity can contribute to smaller HDL by removing CE from 
HDL, and should be addressed in future studies.
Figure 4. ApoA-I of RRMS patients is modified at its tyrosine and tryptophan residues. (a–d) Collision-
induced dissociation (CID) spectra of Trp-50 nitration (a), and Trp-50 mono-, di-, and tri-oxidation (b,c and d 
respectively). Spectra were acquired on analysis of in-gel tryptic digests of the ApoA-I band from HDL3 isolated 
with sequential flotation ultracentrifugation. Modifications were detected in an LC-MS/MS experiment as 
described under Methods. CID fragment ion annotation was according to the nomenclature by Roepstorff and 
colleagues108. (e) Summary of ApoA-I modification sites. Residues that were modified are indicated with ∆ . The 
numbering of the amino acids cited refers to the amino acid sequence of the mature protein.
www.nature.com/scientificreports/
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We found a reduced capacity of serum from RRMS patients to accept cholesterol via ABCG1, in combina-
tion with a reduced ABCG1 mRNA expression in monocytes. These data indicate that in addition to changes 
in the quantity of sHDL, HDL function is impaired in RRMS patients. Furthermore, these results suggest that 
the reduced capacity of serum in combination with the lower expression of ABCG1 on monocytes may result 
in an even more pronounced reduction in cholesterol efflux from MS monocytes in vivo. Cholesterol efflux is 
one of the main anti-inflammatory effects of HDL because it is responsible for maintaining cellular cholesterol 
homeostasis, and hereby regulates the cellular inflammatory phenotype4,53. In line with this, our data show that 
HDL3 of low-BMI RRMS patients is no longer effective in suppressing an inflammation-induced transcriptional 
profile of TNFα , CD40, IL1β and IFNγ in monocytes. We did not observe an effect of HDL on the expression of 
the anti-inflammatory markers CD206, CD163, and TGFβ . Although Sanson and colleagues reported an induc-
tion of several anti-inflammatory genes in murine macrophages54, other reports on the effect of HDL on human 
monocytes show no upregulation of anti-inflammatory genes after incubation with HDL, similar to our results4,55.
Since myeloid cells in the CNS of MS patients are largely derived from infiltrated monocytes56, the predeter-
mined phenotypic and functional characteristics of these cells in the periphery can have important consequences 
for their contribution to MS pathology. Altogether, these findings indicate that the cholesterol acceptance and 
anti-inflammatory capacity of HDL are impaired in RRMS patients, which may contribute to disease progression.
An increase in IR, measured by the IR homeostasis model assessment (HOMA-IR) method, has been reported 
in MS patients, and was reported to be associated with invalidity scores (EDSS)57. In contrast to these findings, we 
found no association between LP-IR and EDSS scores (r = − 0.109, P = 0.781) in the total RRMS patient group, 
nor in RRMS patients with a low BMI, making it unlikely that physical inactivity is responsible for the observed 
differences in our study. The anti-inflammatory MS-therapeutic interferon-β (IFN-β ) can also induce IR by inhib-
iting insulin-induced tyrosine phosphorylation of the insulin receptor substrate 1 protein58. In this study, how-
ever, we found no effect of IFN-β therapy, neither of other patient therapies on the LP-IR or on other measured 
lipoprotein parameters. Although IR is most common in individuals with excess weight and excess fat around the 
waist59–61, IR in lean subjects is not uncommon62,63. Moreover, even in the absence of obesity, the administration 
of inflammatory cytokines in animals causes IR64. In addition, elevated levels of TNFα and IL-6, two cytokines 
that are involved in MS pathology65–67, are proposed to increase IR in patients with chronic inflammatory condi-
tions68,69. This study did not investigate IR directly by means of a HOMA or oral glucose tolerance test. However, 
the NMR-derived LP-IR measurement is strongly associated with both the homeostasis model assessment of 
insulin resistance (r = 0.51) hereby being reflective of hepatic IR, and with glucose disposal rates (r = − 0.53) 
hereby reflecting peripheral insulin sensitivity (85).
Besides an increase in IR, impaired glucose tolerance (IGT) and decreased insulin sensitivity are described 
in MS patients31,70. IR and IGT precede T2D and drive an accelerated risk for cardiovascular disease (CVD) by 
modulating the lipoprotein profile and influencing several mechanisms affecting the endothelium, the vascu-
lar wall, smooth muscle cells, and platelets71–73. Altogether, the shift towards sHDL together with smaller LDL, 
increased TG, larger and more TG-rich VLDL, and a higher LP-IR in the lipoprotein profile of low-BMI RRMS 
patients in this study are typical features of an insulin resistant, pre-T2D-like lipoprotein profile43,44. In T2D and 
CVD patients, not only a similar lipoprotein profile, but also impaired HDL-mediated cholesterol efflux and anti-
oxidant function74–77, and a reduced expression of ABCG1 on monocytes is found, the latter which is described 
to lead to an increase in cellular cholesterol accumulation78. Together, these findings may suggest a pre-diabetic 
state in low-BMI RRMS patients. However, studies that determined the impact of co-morbidities like T2D and 
CVD on MS mortality rates are inconclusive79,80. Although the risk to develop CVD in the total MS population is 
similar to that in controls, the mortality rate due to CVD is higher in MS patients81, and vascular co-morbidities 
present during the disease course of MS can increase the risk of ambulatory disability82. Importantly, low-BMI 
MS patients have an increased mortality rate, which is highest in male subjects with cardiovascular disease as an 
underlying cause of death83. We found a negative correlation between small HDL and BMI in RRMS patients. 
However, this correlation was absent in progressive MS patients. This indicates that the observed changes in 
lipoprotein levels may be related to the ongoing inflammatory process which is predominant in RRMS patients 
compared to progressive patients84. Interestingly, pro-inflammatory monocyte subsets were found to be posi-
tively associated with levels of small HDL in atherosclerosis patients85. Pro-inflammatory monocyte subsets are 
suggested to contribute to the inflammatory responses in MS patients86, but their possible association with lipo-
protein levels needs further clarification.
Changes in HDL function can be caused by modifications of the proteome and lipidome of HDL87–89. Using 
mass spectrometry, we identified the presence of nitrations and oxidations of tyrosine and tryptophan along 
with a + 126 amu modification on tyrosine residues in HDL3-derived ApoA-I of RRMS patients. Some of these 
changes in ApoA-I have been described to affect HDL function48. Interestingly, levels of the leukocyte-derived 
haemprotein myeloperoxidase (MPO), which is described to modify ApoA-I in vitro90 and in vivo48, are increased 
in MS patients91,92. Therefore, MPO may be involved in the observed ApoA-I modifications and impaired HDL 
function. In addition to these observations, we found a modification of + 126 amu, for which three possible mod-
ification candidates can be suggested: iodination, glycation (162 amu minus two water molecules) and octanoy-
lation. Merely the latter modification is consistent with the observed significant increase in retention time of 
the modified peptide. The presence of these modifications on tyrosine and tryptophan indicates that these aro-
matic residues are preferred modification sites of ApoA-I. The exposition of the Trp domains in the center of the 
ApoA-I ring structure probably makes them more vulnerable for modifications. Importantly, the Trp-50 and 
Trp-72 domains are both responsible for lipid-binding of ApoA-I93, which is essential for small HDL to mature 
to larger HDL particles. Furthermore, interactions between the aromatic residues Tyr-100, 115 and 236 stabilize 
lipid-free ApoA-I particles93. Altogether, our results show that ApoA-I of RRMS patients is modified at its tyros-
ine and tryptophan residues, but the exact contribution of these modifications to HDL dysfunction in MS needs 
further investigation.
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In summary, our data show that RRMS patients display an altered lipoprotein profile, which is especially pres-
ent in RRMS patients with a low BMI. Furthermore, the anti-inflammatory and cholesterol acceptance properties 
of HDL are impaired, which may enhance the inflammatory response and promote disease progression in MS. 
In addition, the HDL alterations may predispose MS patients to additional health risks such as CVD and T2D. 
Further studies are needed to determine the impact of reduced HDL function on MS disease progression and 
co-morbidities. Knowledge on disturbances in lipoprotein levels and function may help to explain the variability 
in MS disease course and outcome, and may pave the way for the development of tailored therapies for specific 
MS patient subgroups.
Materials and Methods
Subjects. A total of 89 controls, 36 RRMS, and 25 progressive MS patients were recruited after providing their 
informed consent. Relapsing-remitting patients were in remission when participating in the study, as at time of 
sampling there was no evidence of an active flare up. Progressive MS patients include both secondary progressive 
MS patients and progressive relapsing MS patients. MS patients were included independent of their medication 
status. An overview of the therapies in the patient subgroups is shown in Supplemental Data Table 1. Exclusion cri-
teria for patients and controls were reported hypercholesterolemia, cardiovascular diseases, diabetes, pregnancy, 
cancer, liver disease, and treatment with cholesterol modifying agents. The mean time since diagnosis for all RRMS 
patients was 8.8 ± 1.1 years. The mean time since diagnosis for low-BMI RRMS patients was 13 ± 3.4 years.
Sample processing. EDTA-plasma was obtained after centrifugation of fasting blood samples at 400 g for 
ten minutes and another ten minutes at 1,500 g to remove remaining cells. Cells were cultured freshly. Plasma was 
immediately stored at − 80 °C by the University Biobank Limburg (UBiLim). All plasma samples were analyzed 
within 6 months after collection. The NMR analysis was performed for 89 controls, 36 RRMS and 25 progressive 
MS patients. For the other experiments the maximum amount of samples available in the University Biobank 
were used for each experiment. Study information on healthy controls (age, gender, weight, and length) and MS 
patients (age, gender, weight, length, therapy, EDSS score, time since disease onset, and relapse rate) was obtained 
from UBiLim. The mean EDSS for the RRMS patients was 2.3 ± 0.3 (for low-BMI RRMS patients 3.2 ± 0.6), 
and for the progressive MS patients 4.9 ± 0.3. The study was approved by the Medical Ethics Committees of 
Hasselt University and UZ Leuven. All procedures followed were in accordance with institutional guidelines and 
regulations.
Nuclear magnetic resonance spectroscopy. Fasting plasma samples were thawed and immediately 
analyzed using the 400-MHz proton Vantera Clinical Analyzer® (Liposcience, Raleigh, North Carolina)94, the 
first NMR providing lipoprotein tests approved by the US Food and Drug Administration for use as a clinical 
instrument source. Particle size, concentration and subclass (large, medium, small) count were measured for all 
lipoprotein classes (HDL, LDL, VLDL). In addition, TG concentrations and VLDL-TG were measured. The NMR 
analysis involved measurement of the sample, and the deconvolution of the signal and conversion of the signal 
into specific lipoprotein subclass concentrations. The 400-MHz proton NMR spectrum of each plasma sample was 
measured, producing a signal at ~0.8 ppm, which was derived from the methyl group protons of the lipids carried 
in the lipoprotein subclasses. The signals at ~0.8 ppm had unique and distinctive frequencies and line shapes, each 
of which were accounted for in the deconvolution analysis model. The lipoprotein insulin resistance (LP-IR) index 
measured by the NMR is calculated from three lipoprotein subclasses (large VLDL, small LDL and large HDL) 
and three particle sizes (VLDL, LDL and HDL). Although the LP-IR is an indirect measure of IR, it is strongly 
associated with both the homeostasis model assessment of insulin resistance (r = 0.51), hereby being reflec-
tive of hepatic IR, and with glucose disposal rates (r = − 0.53) hereby reflecting peripheral insulin sensitivity95. 
The results are reported on a scale ranging from 0 (most insulin sensitive) to 100 (most insulin resistant).
LCAT mass. Lecithin - cholesterol acyltransferase (LCAT) mass was measured with a commercial ELISA 
(Alpco Diagnostics, Salem, New Hampshire)96. In brief, an anti-LCAT monoclonal antibody (MoAb) coated 
96-well plate was incubated for 2 hours with freshly thawed fasting plasma samples and standards in duplicate. 
Unbound material was washed away, and horseradish peroxidase-labeled anti-LCAT MoAb was added for 1 hour. 
After the incubation and subsequent washes, the antibody/LCAT/enzyme complex was incubated with a substrate 
solution for 15 minutes and terminated with a stop reagent for another 15 minutes. The color intensity of the 
enzyme reaction was measured with a microplate reader at 492 nm.
ABCA1 and ABCG1 cholesterol efflux capacity. Serum was derived from plasma by adding calcium97. 
ATP-binding cassette transporter A1 (ABCA1) - and ABCG1 -specific cholesterol efflux to serum was quanti-
fied using baby hamster kidney (BHK) cells expressing the mifepristone-inducible human ABCA1 or ABCG1 as 
described previously98,99. In brief, mock and transfected BHK cells expressing the mifepristone inducible human 
ABCA1 cDNA were cultured in 10% FCS (Atlanta Biologicals, Norcross, Georgia) labeled for 18 hours with 1 μ Ci/ml 
3H-cholesterol (Perkin Elmer, Waltham, Massachusetts) in DMEM (Life technologies, Grand Island, New York) sup-
plemented with 0.01% BSA and 10 nM Mifeprestone (Life technologies). Excess cholesterol was washed away with 
1x phosphate buffered saline (PBS). DMEM medium containing 0.01% BSA and 1% of the serum of controls or MS 
patients was added as a cholesterol acceptor together with 10 nM Mifeprestone to induce ABC transporter specific 
cholesterol efflux for 4 h. After 4 hours, media were collected and filtered through a 1.2 μ m 96-well filter plate (Pall 
Corporation Life Sciences, Port Washington, New York) and cells were lysed in 0.5 ml of 0.1% SDS and 0.1 M NaOH. 
Liquid scintillation counting (MicroBeta 1450 Liquid Scintillation, Perkin Elmer) was used to measure radioactive 
counts of cholesterol in media and cell fractions. Results were expressed as the percentage of total counts effluxed into 
the media after 4 hours of efflux. HDL is known to be the major lipoprotein contributing to the process of cholesterol 
efflux, but the use of whole serum for this experiment is more physiologically relevant than using solely HDL.
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Monocyte isolation and cell culture. After separation from plasma, blood was diluted with 1x PBS 
without Ca2 + and Mg2 + (Lonza, Verviers, Belgium) (ratio 1:1), supplemented with 2 mM EDTA. The diluted 
blood samples were subjected to density gradient separation on Ficoll-Paque (ratio 2:1) (GE Healthcare Life 
Sciences, Buckinghamshire, UK) and centrifuged for 20 minutes at 400 g. After centrifugation the layer of 
peripheral blood mononuclear cells (PBMCs) was collected and washed twice in 1x PBS supplemented with 
2 mM EDTA. CD14 + monocytes were isolated from PBMCs using EasySep™ human CD14 positive selection 
(Stemcell Technologies, Grenoble, France) according to manufacturer’s instructions. After isolation, cells were 
re-suspended in RPMI 1640 supplemented with 0.5% penicillin/ streptomycin, 1% non-essential amino acids, 1% 
sodium pyruvate and 2.5% FCS (low serum culture medium) and placed in 24 well culture plates at a density of 
0.5 × 106 cells per well. Cells were pre-incubated with HDL3 (60 mg/dl) or left untreated for four days, followed 
by an overnight stimulus with 100 ng/ml lipopolysaccharide (LPS) (E. coli O55:B5, Sigma-Aldrich, Diegem, 
Belgium). Previous dose response studies within our group and studies by others have shown that this LPS con-
centration gives a good induction of pro-inflammatory genes in human monocytes100,101.
Isolation of HDL3 from plasma. Butylated hydroxytoluene (BHT, Sigma-Aldrich) was added (50 μ g/ml) 
to freshly isolated plasma immediately to protect lipoproteins from auto-oxidation during the isolation proce-
dure. HDL3 (density 1.125–1.210 g/ml) were isolated using sequential density floatation ultracentrifugation102. 
After isolation, HDL3 was dialyzed extensively at 4 °C against 1x PBS and afterwards against low serum culture 
medium for use in cell cultures. Lipopolysaccharide (LPS) content in isolated HDL3 was determined using the 
Chromogenic Limulus Amebocyte Lysate assay kit (Genscript Incorperation, Aachen, Germany). Isolated HDL3 
contained a neglectable amount of endotoxins (< 1.8 × 10−4 pg/μ g HDL3). HDL3 were sterilized using a 0.22 μ M 
filter, stored in sealed tubes under a layer of nitrogen at 4 °C in the dark to prevent auto-oxidation, and were used 
within two weeks after isolation.
Real-time quantitative reverse transcription polymerase chain reaction. Total RNA was isolated 
using the High Pure RNA isolation kit (Qiagen, Venlo, the Netherlands) according to manufacturer instructions. 
Total RNA concentration and RNA purity were verified with a Nanodrop Spectrophotometer ND-1000 (Isogen 
Life Science, St-Pieters-Leeuw, Belgium). RNA was reverse transcribed using a cDNA synthesis kit (Quanta, 
Gaithersburg, USA). Gene expression was measured with quantitative PCR (qPCR) using the StepOnePlus™ 
Real-Time PCR System (Applied Biosystems, Halle, Belgium). Fast SYBR Green (Applied Biosystems), 0.3 μ M 
forward and reverse primers and 12.5 ng cDNA were used per qPCR reaction using universal cycling conditions 
(10 ’ 95 °C, 15 ” 95 °C and 1’ 60 °C, 40 cycles)103. PCR products were loaded on 2% agarose gels to confirm the 
specificity of amplification and the absence of primer dimer formation. Data were analyzed using the Δ Δ Ct 
method104 and are shown as fold change over controls. Expression levels were normalized using the most stable 
housekeeping genes, determined with geNorm105. The used primer sequences for real time PCR are listed in 
Supplemental Data Table 2.
Mass spectrometry. ApoA-I SDS PAGE and in-gel digestion – The protein concentration of HDL3 was 
determined using the bicinchoninic acid assay (Thermo Scientific, Erembodegem, Belgium), with albumin as 
the standard. HDL3 (3 μ g) isolated by sequential ultracentrifugation was separated by Tris-glycine SDS-PAGE on 
12% polyacrylamide gels for 1 hour at 200 V. The Coomassie Brilliant Blue G-250 stained ApoA-I band with an 
apparent Mr of 23 kDA was cut from the gel, destained and digested overnight at 37 °C using sequencing-grade 
porcine trypsin (Promega, Leiden, the Netherlands). The tryptic peptides extracted from the gel, were speed-
vac dried and stored at − 20 °C until analysis. LC-MS/MS analysis – An Easy-nLC1000 liquid chromatograph 
(Thermo Scientific, Erembodegem, Belgium) was on-line coupled to a mass calibrated LTQ-Orbitrap Velos Pro 
(Thermo Scientific) via a Nanospray Flex ion source (Thermo Scientific) using sleeved 30 μ m ID stainless steel 
emitters (spray voltage + 2.3 kV, capillary temperature: 200 °C)106. The SpeedVac dried tryptic peptide mixture 
was dissolved in 40 μ l buffer A (0.1% v/v formic acid in Milli-Q water) of which 10 μ l was loaded, concentrated 
and desalted on a trapping pre-column (Acclaim PepMap 100 C18, 75 μ m ID × 2 cm nanoViper, 3 μ m, 100 Å, 
Thermo Scientific) at a buffer A flow rate of 5 μ l/min for 5 minutes. The peptide mixture was separated on an 
Biosphere C18 column (50 μ m ID × 20 cm, 5 μ m, 120 Å, NanoSeparations, Nieuwkoop, the Netherlands) at a flow 
rate of 100 nL/min with a linear gradient in 180 minutes of 0 to 70% buffer B (0.1% v/v formic acid in acetoni-
trile) in buffer A. MS data were acquired in a data-dependent mode under direct control of the Xcalibur software 
v 2.2, selecting the fragmentation events based on the top six precursor abundances in the survey scan (350–
2000 Th). Data analysis - The mass spectrometric RAW data was analyzed using Proteome Discoverer software 
v.1.4 (Thermo Scientific) with build-in Sequest v.1.4 and interfaced with an in-house Mascot v.2.5 server (Matrix 
Science, London, UK). MS/MS spectra were searched against the SwissProt human fasta database (Version 
June 2015; 42121 entries) and peptide scoring for identification was based on following search criteria: enzyme 
trypsin, maximum missed cleavages 2, precursor mass tolerance 30 ppm and fragment mass tolerance 0.5 Da. 
Carbamidomethylation of cysteine and oxidation of methionine, histidine and tryptophan were set as fixed and 
dynamic modifications, respectively. Error tolerant searches in Mascot were used to detect unspecified peptide 
modifications using the Unimod database collection of protein modifications for mass spectrometry107. Output 
files of both search engines were uploaded and automatically validated in Scaffold v.4.4 (Proteome Software) using 
the Peptide Prophet and Protein Prophet algorithm with a preset minimal peptide and protein identification 
probability of 95% and 99%, respectively. The peptide false discovery rate was < 0.5%.
Statistical analysis. For descriptive statistics, one way ANOVA or Kruskal – Wallis tests were performed 
in GraphPad Prism (Windows version 6). Differences in gender were assessed using chi-square tests. Univariate 
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multiple linear regression models for each dependent response variable were fitted using SAS (Windows version 
9.4). For response variables for which the error normality assumption was not met, logarithmic or square root 
transformations were performed. A backward-elimination approach was performed in each univariate multiple 
linear regression model (until all remaining variables had P < 0.05), starting from the model “response = group 
age BMI gender group*BMI group*age group*gender BMI*age BMI*gender age*gender”. A post hoc Tukey 
or Bonferroni test was used to correct for multiple testing. Statistical significance is presented as *P < 0.05, 
**P < 0.01, ***P < 0.001, and ****P < 0.0001 in all figures. The Pearson correlation coefficient was used for linear 
regression analysis with continuous variables. The absence of multicollinearity in the linear regression models 
was verified by calculating the variance inflation factor. Continuous variables are presented as mean ± SEM. The 
authors had full access to and take full responsibility for the integrity of the data.
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